Advanced Filters
noise
Found 1,623 clinical trials

Novel Digital Patient-Reported Outcomes Tool for Diabetes Management

Investigators will conduct a hybrid type 1 effectiveness-implementation randomized controlled trial (RCT) to evaluate the effectiveness of iMatter2 versus usual care on reduction in HbA1c at 12-months (primary outcome) among patients with Type 2 diabetes (T2D).

18 years of age All Phase N/A
N Natalia Garban

Type 2 Continuous Glucose Monitoring Academy

The goal of this clinical trial is to evaluate the Impact of Continuous Glucose Monitoring Academy Education Curriculum Versus Standard Care on Glycemic Outcomes for Youth With Type 2 Diabetes (T2D): The first aim is to determine how feasible it is to adapt the Continuous Glucose Monitoring Academy curriculum to …

8 - 21 years of age All Phase N/A

A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)

The main purpose of this study is to evaluate additional dosing options for dulaglutide in pediatric participants with Type 2 Diabetes. Participation in this study will last about 8 months.

10 - 17 years of age All Phase 3

UBC Breakfast Study 2.0

Type 2 diabetes (T2D), a prevalent metabolic disorder impacting >3 million Canadians, is characterized by insulin resistance and high blood glucose. Chronically elevated blood glucose (i.e., hyperglycemia) and swings in glucose (i.e., glucose variability) contribute to complications of T2D. Specifically, post-meal hyperglycemic spikes are independent risk factors for cardiovascular disease …

30 - 79 years of age All Phase N/A
K Kelly Henry, RN,CDCES,CPT

Diabetes Management Using Continuous Glucose Monitors and Remote Patient Monitoring in Underserved Populations

The goal of this 52 week prospective study is to learn whether a Diabetes Care Management Program using a continuous glucose monitor (CGM) and remotely monitoring (RPM) glucose readings can help improve glucose levels and diabetes related distress in individuals with uncontrolled type 2 diabetes. The CGM and RPM are …

18 years of age All Phase N/A

A Study to Evaluate Pharmacokinetics of LY3209590 in Pediatric Participants With Type 2 Diabetes Mellitus

The main purpose of this study is to evaluate how much of LY3209590 gets into the blood stream after a single dose and how long it takes the body to remove it in pediatric participants with Type 2 Diabetes Mellitus (T2DM). The study will last for approximately 100 days.

10 - 17 years of age All Phase 1
M Margaret Zupa, MD MS

Enhancing Telemedicine for T2D

The goal of this pilot clinical trial is to assess feasibility of an intervention to deliver comprehensive, high-quality diabetes care through telemedicine among adults with type 2 diabetes who use insulin and have multiple chronic health conditions. The main question it aims to answer is: Is an enhanced telemedicine intervention …

18 - 80 years of age All Phase N/A
J Jamie Burr, PhD

Feasibility of Aerobic Exercise With Blood Flow Restriction Training in People Living With Type 2 Diabetes

The goal of this trial is to learn if blood flow restriction training with treadmill walking is possible for individuals living with type 2 diabetes. It will also learn about how the blood flow restriction with treadmill walking could improve health. The main questions it aims to answer are: Is …

19 - 64 years of age All Phase N/A
P Priya Loomba, Dr.

Study to Assess Safety, Tolerability, PK, and PD of Multiple Doses of ZE63-0302 Administrated Orally in T2DM Patients.

A Phase 1b study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of multiple doses of ZE63-0302 administrated orally in T2DM patients.

18 - 65 years of age All Phase 1
J Jenna Hauben

Food and Fitness With Medicine (FFWM)

Food and Fitness with Medicine (FFWM) is a 24-week randomized controlled trial (RCT) enrolling 200 post-menopausal women (PMW) with stage 2 cardio-kidney metabolic (CKM) syndrome and type-2 diabetes (T2D) within 6 weeks of initiating glucagon-like peptide-1 receptor agonist (GLP-1RAs) to: 1. Examine discontinuation rates of GLP-1RAs (primary outcome); 2. Compare …

18 years of age Female Phase N/A

Simplify language using AI